Blog Empty Image

Ozempic (Semaglutide) is a glucagon-like peptide 1 (GLP-1) receptor agonist indicated as:

I. an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
II. to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease.
III. an adjunct to diet and exercise to improve glycemic control in adults with type 1 diabetes mellitus.

a. I only
b. III only
c. I and II only
d. II and III only
e. All


Ozempic (Semaglutide) is a glucagon-like peptide 1 (GLP-1) receptor agonist indicated as:

I. an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
II. to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease.
III. an adjunct to diet and exercise to improve glycemic control in adults with type 1 diabetes mellitus.

a. I only
b. III only
c. I and II only
d. II and III only
e. All

Answer: (c) I and II only. Ozempic (Semaglutide) is a glucagon-like peptide 1 (GLP-1) receptor agonist indicated as:

1. an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
2. to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease.

It is available as 0.5 or 1 mg subcutaneous injection. It is not indicated for use in type 1 diabetes mellitus or treatment of diabetic ketoacidosis.

The recommended starting dose is 0.25 mg once weekly. After 4 weeks, increase the dose to 0.5 mg once weekly. If after at least 4 weeks additional glycemic control is needed, increase to 1 mg once weekly. It can be administered once weekly at any time of day, with or without meals.

The oral dosage form of this drug is available under the brand name of Rybelsus. It is available in 7 mg or 14 mg tablets. The tablet dosage form is indicated as:

1. an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

The most common adverse reactions, reported in greater than 5% of patients treated with Ozempic (Semaglutide) are: nausea, vomiting, diarrhea, abdominal pain and constipation.

Try our Naplex QBank. www.pharmacyexam.com **Please note: This type of question will not show up in an MPJE. We are just posting to MPJE group for knowledge.